2023 WILL BE A "BIG" YEAR FOR ERBA TRANSASIA WITH GREAT SUCCESSES COMING FROM 150 COUNTRIES

Please share key achievements of 2022.

The year 2022 has been another year of recognition for Transasia in its pursuit of helping create a "Healthier and Happier World". We have been focused on creating a costeffective, innovation-driven clinical diagnostics ecosystem for doctors and patients worldwide. In line with this, our R&D teams in India, Europe and USA collaborated to introduce the latest advancements in areas such as molecular diagnostics, hematology, biochemistry and critical care. Some of the key achievements include:

• 20,000+ units of Erba hematology analyzers sold in just 3 years, setting a new benchmark, globally.

• The EC90, Erba’s next generation electrolyte analyser with an innovative biosensor technology witnessed a global launch, generated much interest, and promises to be a new trend maker in the electrolyte testing space.

• Erbamdx Monkeypox Real Time PCR kit, the first “Made in India” highly sensitive RT Pcr-based test kit for Monkeypox Virus was also launched, paving the way for easy to use and affordable testing of infectious diseases, a growing concern for India and the emerging countries

• The all new Erba XL 640 analyzer with conveyor rack system and Erba XL 200 are helping us further strengthen our presence in clinical chemistry

On the global front, we now have a true state-of-the-art 10,000 sq ft corporate office in Dubai Science Park. Equipped with multiple large conference rooms, product demo centre and latest training facilities, Erba Diagnostics FZ LLC (our global HQ) will offer quality services and support to all our partners worldwide. We also expanded our global presence with subsidiaries in several more countries.

Please share your strategy for business planning and forecast.

Being the leader in the Indian IVD industry, our strengths of innovation, accessibility and affordability will continue to drive our future growth. Manufacturing in India has helped us provide Atma Nirbhar products that are customized to fulfill India’s needs of affordability and reach, especially in tier II IV towns – the real India. Our other major growth driver will be our people, who are making our technologies accessible to the 70% Indians residing in the remote locations with no access to sometimes even the most basic diagnostic solutions. So, while on one hand our teams of sales and service experts, the largest in the Indian IVD industry, ensure that we manage disruptions in last mile distribution, on the other hand, we have a team of dynamic leaders, who bring in years of rich and diverse experience.

We will continue to further harness our capabilities to partner with hospitals and laboratories. Availability of trained experts is the biggest challenge faced by tier II, III and IV cities. So, to enable thousands of new diagnostic laboratories to be opened in rural India, Transasia under its CSR plans, has established training schools to provide high quality training for laboratory technicians who will be amongst the best laboratory technologists that India has.

How does ensuing year 2023 look like for you?

With our mission of achieving Healthy and Happy World, made possible by the Atma Nirbhar Bharat initiatives, we are excited that the year 2023 will be "The Year of Transasia”. The launch of Erba-transasia 2.0, will be a game changer, and will place us globally among the 5 "Total Solutions Diagnostics Companies”. This will mark the culmination of our decadelong smart strategy of acquiring technology companies based in Europe and USA to fill the technology gaps that we have had in India. The 14 R&D companies in Europe and USA that we acquired in last 10 years, have been working tirelessly to develop several new exciting technologies and products, which will make Erba-transasia a truly global Total Solutions company. These new exciting products are backed by unique patented technologies, developed in-house, and will finally be rolled out in the next 1-2 years. The product range will include Chemiluminescence systems, Molecular testing systems and Ai-based innovative Hematology systems.

Transasia already has five manufacturing units in India and 2 overseas plants in Europe and USA which are working very hard to meet the global demand for our products. To meet the expected huge demand for our new products like Chemiluminiscence and molecular testing, we have started work on a brand new and largest “Factory of the future”, which will churn out millions of high quality, affordable products every year. Working in tandem are our 12 subsidiary offices that will meet the demand from over 150 countries where our products are being widely used to help their people become Healthy and Happy.